Lorenzo Fornaro

20PUBLICATIONS
122CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsiesPredictive and prognostic markersSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 12, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

|Jul 29, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

|Jun 01, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

|Aug 20, 2025
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.

Andrea Botticelli, Chiara Cremolini, Simone Scagnoli

|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.

Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi

|Mar 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

Markus Moehler, Do-Youn Oh, Ken Kato

Pageof 4

Frequent Collaborators

11 joint publications

Caterina Vivaldi

5 joint publications

Andrea Casadei-Gardini

4 joint publications

Gianluca Masi

4 joint publications

Francesca Salani